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ABSTRACT 
In the recent years, Health Technology Assessment (HTA) processes specific to diagnostics and 
prognostic tests have been created as a response to an increasing pressure on health systems to 
decide not only which tests should be used in practice, but also the best way to proceed, clinically, 
from the information they provide. These technologies differ in the way value is accrued to the 
population of users, by depending critically on the value of downstream health care choices. This 
paper defines an analytical framework for establishing the value of diagnostic and prognostic tests for 
HTA in a way that is consistent with methods used for the evaluation of other health care 
technologies. It assumes a linked-evidence approach where modelling is required, and incorporates 
considerations regarding a number of different areas of policy such as personalised medicine. We 
initially focus on diagnostic technologies with dichotomous results, and then extend the framework by 
considering diagnostic tests that provide more complex information, such as continuous measures 
(for example, blood glucose measurements) or multiple categories (such as tumour classification 
systems). We also consider how the methods of assessment differ for prognostic information or for 
diagnostics without a reference standard. Throughout, we propose innovative graphical ways of 
summarising the results of such complex assessments of value. 
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INTRODUCTION 
 
Funding decisions regarding health technologies are increasingly supported by an explicit 
examination of the available evidence, with the aim of determining which technology is expected to 
confer most value for use in clinical practice ± a process called Health Technology Assessment 
(HTA). This process is well established for medicinal products such as drugs, and is explicitly used to 
support policy decisions in many jurisdictions(1). However, some jurisdictions have extended their 
scope and defined separate HTA processes for diagnostic (including screening) and prognostic 
technologies, examples being the Diagnostics Assessment Programme in the UK(2) (created in 2010) 
and the HTA of co-dependent technologies in Australia(3) (created in 2011). This responds to the 
increasing pressure on health systems to decide not only which tests should be used in practice, but 
also the best way to proceed, clinically, from the information they provide; HTA provides the ideal 
framework to inform these two interrelated questions.  
 
Diagnostics and prognostics (for simplicity we will refer to these as tests) are clinical investigations 
WKDWSURYLGHLQIRUPDWLRQRQWKHSDWLHQWWKHSDWLHQW¶VKHDOWKRURQWKHREVHUYHGRUH[SHFWHGHIIHFWV
of treatment. This information may contribute to diagnosis by helping to detect or to exclude disease, 
or to prognosis by predicting the chance of relevant future health outcomes in a particular patient.(4) 
These technologies differ from medicinal products in a crucial way, relating to the indirect mechanism 
of accruing value which has been recognised by HTA DJHQFLHV³Post outcomes of interest [from 
diagnostic tests] follow from treatments that are either initiated or not initiated based on the results of 
the tests´(5)  DQGWKHUHLVWKXV³the need to consider the benefits of their joint use [of the diagnostic 
technology and the treatment], as distinct to the benefit RIHDFKWHFKQRORJ\LQLVRODWLRQ´(6). Basing 
decisions on these technologies over value to patient outcomes such as Quality Adjusted Life Years 
(QALY) has been increasingly recognised, not just in the policy context(7, 8) but also in the context of 
the design of evaluative research(9-11).  However, while the principles for a distinct HTA process may 
be well justified, there is insufficient guidance on how specifically to adapt the methods of HTA to 
tests, in a way that reflects the features of these technologies and to allow decision makers to clearly 
understand the drivers of value.(8, 12)  A better, and more integrated, evaluation can also align 
interests across stakeholders.(8, 13, 14) 
 
Early work by Phelps and Mushlin(15) set out such an approach to the evaluation of diagnostic tests 
using cost-effectiveness as a basis. The authors focussed on a single dichotomous diagnostic test, 
i.e. one that distinguishes two subgroups such as presence or absence of disease. Also, the auWKRUV¶
viewpoint was from a Research and Development (R&D) context and considered, for example, pricing 
strategies and development priorities. Despite some additional work specific to a particular 
application(16), there has been limited effort to extend such a framework in a comprehensive and 
general fashion.  
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This paper thus aims to define an analytical framework for establishing the value of diagnostic and 
prognostic tests for HTA in a way that is consistent with methods used for the evaluation of other 
health care technologies. It extends the work by Phelps and Mushlin to consider i) the HTA 
perspective, typically focussing on informing funding decisions, ii) the specificities of prognostic, and 
not just of diagnostic tests, and iii) the fact that tests are becoming increasingly complex, with results 
going beyond dichotomous.  We begin by clearly laying-out the specific characteristics of these 
technologies that are of relevance to HTA, notably, the mechanism of accrual of value. Then we 
present a methodological framework for HTA of tests, first by focussing on technologies with 
dichotomous results. We then extend the framework by considering tests that provide more complex 
information, such as continuous measures or multiple categories (such as tumour classification 
systems). Throughout, we suggest graphical ways of summarising the results of such complex 
assessments of value.  
 
  
MECHANISM OF VALUE FOR DIAGNOSTICS AND PROGNOSTICS 
 
Within HTA, technologies can be considered of value if they present health benefits to the patient 
SRSXODWLRQWKDWZLOOUHFHLYHWKHPEHQHILWVGLVFRXQWHGRIDQ\KDUPVRUWKHµKHDOWK¶LPSDFWRIWKH
technology). Some jurisdictions consider, alongside health impact, the expected health losses to other 
patients from displaced treatments as result of any additional funding needs (a net health benefit 
approach).(17) This paper will consider either case, as long as the metric of value can be represented 
using a single unit, encompassing health or net health. The framework is equally applicable where a 
wider perspective on benefits is taken or where patient preferences are incorporated into metrics of 
benefit. 
 
In terms of the health impact of diagnostic and prognostic technologies, the mechanism of value 
accrual is more complex to that of other health care technologies. Diagnostic and prognostic 
technologies identify the level or magnitude of attributes that determine (diagnostic) or predict 
(prognostic) health outcomes with and without treatment (where treatment refers to a course of action 
which potentially impacts on health, for example, treatment with a drug, undergoing a biopsy, 
adopting a life-style intervention or even watchful waiting). While these technologies may affect health 
directly (e.g. as a result of adverse events from undergoing a test procedure), their main value 
typically lies in identifying patients expected to benefit from distinct treatments (or other regimens of 
health care such as strategies for the prevention of disease, illness or injury).(18) The mechanism by 
which value is generated is not direct, but instead arises from tailoring treatment decisions to patient 
characteristics. It can be structured using three interlinked components(15): 
  
i)   Classification: When a test is applied to individual patients it may return one of a set of possible 
results. In some cases, the test results can be directly used to define the patients being treated, as 
is the case with a test returning a positive or negative result. However, where treatment options are 
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fewer than the number of possible results from the test, there is the need to apply a classification 
rule. The classification rule pools some of the test results to identify the groups of patients who will 
be treated differently ± for convenience we refer to these as treatment groups. For example, for a 
test reporting results on a continuous scale, a cut-off may be needed to classify patients into two 
treatment groups (i.e. those above and below the cut-off), one of which may benefit more from 
treatment than the other. It is, however, important to evaluate the use of alternative classification 
rules. For example, we could alternatively choose not to treat patients with extremely high or 
extremely low test results, if that proves more valuable, and use two cut-off values instead of one. 
Patients with low and high test results, not treated, are, according to our definition part of the same 
treatment group. However, given these two subgroups may have different prognosis and resource 
use profiles, they may need to be considered separately in a decision model.  
 
ii)  Choice: When testing, and after knowing the results of the test and classifying patients into 
treatment groups, there are choices to be made about which treatments those treatment groups 
will receive. Such choices are critical as the value of a test often does not depend on the test itself 
but on the capacity to benefit from better therapeutic choices. This component thus relates to 
therapeutic choices made for each treatment group after knowing the classification.  
 
iii) Outcomes: This component involves the quantification of the consequences of treating the 
distinct treatment groups (or subgroups within these if the model is non-linear) in terms of 
(net)health. This is an important component as the value of testing is bound by the outcomes 
associated with each treatment option.  
 
These multiple, interlinked, components make these technologies distinctive from treatments(19). In 
practice, these principles should be used when specifying the decision problem, the clinical pathways 
for modelling and the value proposition of the new test (9, 12).  Where evidence is available 
separately for each of the components of value, (net)health can be determined by mathematical 
models using the relations established above ± the generally endorsed linked-evidence approach (5, 
19-21) akin to a decision modelling approach often used in cost effectiveness.(22)   
 
Diagnostics and stratified medicine 
The literature on the value of heterogeneity and stratified decision making directly relates to this 
mechanism of value accrual with diagnostic and prognostic tests.(23-25) Heterogeneity is defined as 
the variation in outcome of a population (variability) that can at least partly be explained by some 
attribute of interest.(26)  Heterogeneity is valuable insofar as it allows treatment decisions to be 
stratified across different subgroups so as to generate gains in (net)health; but, for heterogeneity to 
be identified, tests need to be applied that identify the subgroup an individual patient belongs to. 
However, the body of literature on evaluation of heterogeneity(27, 28) is seldom explicit about the 
need to test, and whilst there may be some consideration for the direct health effects of testing such 
as adverse events and the costs of the tests, it rarely makes explicit the potential for classification 
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errors and the fact that there may be alternative tests. For the purpose of this paper, we will interpret 
the value of heterogeneity as the value of optimal treatment once patients have been correctly 
identified for the heterogeneous attribute of interest (value of the perfect testing). Such value is 
unlikely to ever be realised in practice, but it is important to have an idea of the potential gains from a 
perfect test.  
 
With the recent developments in genetic profiling, another policy area receiving much attention is 
personalised care(8 , 14, 29)ZKLFKFRQVLGHUVWUHDWPHQWVWUDWLILFDWLRQWRLWV¶OLPLWRIWKHLQGLYLGXDO
Despite full personalisation still being some way off achievable, it is believed that the identification of 
relevant sources of heterogeneity through pharmacogenetics will allow further targeting of R&D to 
allow for full personalised care.(30) A few such developments have been through HTA processes, 
most comprising of targeted treatment to patients more likely to respond as identified through a 
genomic test: recent examples are trastuzumab (e.g. NICE TA257), imatinib  (e.g. NICE TA209) or 
gefitinib (e.g. NICE TA258). The HTA of co-dependent technologies in Australia was created in 
response to these test/treat strategies.(3) 
 
Identifying relevant options for comparison when establishing value  
Value is in essence relative and can only be determined in comparison to something else. The well-
established HTA process for treatments specifies that all possible alternatives should be included in 
an appraisal so that the value of each can be compared(31). This same principle should also apply to 
tests. Options that do not involve testing should be considered alongside those involving relevant 
tests (including tests focussing on different attributes that can also explain heterogeneity) and the 
possibility of using multiple tests or sequences of tests. For each test, alternative classification options 
from test results should be considered, and alternative treatment decisions should also be evaluated. 
Therefore, all possible combinations of tests, classifications and treatments need to be considered. 
 
 
VALUATION FRAMEWORK  
 
Dichotomous test results 
We start by revisiting the Phelps and Mushlin(15) framework (based on a single dichotomous 
diagnostic test and a single treatment option), taking an evaluative perspective instead of an R&D 
SHUVSHFWLYH7UXHµGLVHDVH¶VWDWXVLVDVVXPHGNQRZQLQHYDOXDWLQJWKHWHVWVWKURXJKWKHFRQFRPLWDQW
application of a reference test, a test that is definitive for a particular disease.  
 
Figure 1 (top panel) represents the decision problem using the conventional decision tree diagram. 
Such diagrams are useful to identify the different options for comparison, and to list and structure the 
inputs needed to evaluate the (net)health impact of the alternative options. The first node from the left 
(a decision node) represents the decision of whether or not to use a certain test. Note that, for 
simplicity, the diagram does not include the option of using the reference standard for diagnosis, 
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although this should be considered where relevant. The second node identifies the true status of 
patients with diseased patients identified as D+ and healthy patients as D-; this is a stochastic node 
reflecting the expected likelihood of any single patient being diseased (probability of disease (P[D+], 
or prevalence). The third node available describes the distribution of test results within disease status 
groups. In the case of a dichotomous test result no classification rule is required. Thus, the test 
directly classifies patients into two treatment groups, one where the test is positive, T+, and another 
where the test is negative, T-.  The decision tree in Figure 1 includes the test results conditional on 
the true disease status ± i.e. the test performance (its accuracy). To describe performance, two 
quantities are often used: sensitivity, referring to the probability that the test of interest is positive 
when the disease is present (true positives, P[T+|D+]); and specificity, which refers to the probability 
that the test is negative when the patient is not diseased (true negatives, P[T-|D-]).(32) With an 
µLPSHUIHFW¶WHVWVRPHRIWKHSDWLHQWVPD\EHLQFRUUHFWO\LGHQWLILHGLQZKLFKFDVHVHQVLWLYLW\DQGRU
specificity will assume values lower than 1.  
 
Figure 1: Decision tree schematic: dichotomous results and two treatments available 
 
Diagnostic with reference standard 
      
 
Prognostic or diagnostic without reference standard 
             
 
 8/22 
 
 
 
Treatment choices follow classification. If the test is not made available, should all or no patients be 
treated? When testing, should only patients who tested positive be treated, or also those who tested 
negative? Setting up such an explicit decision tree allows the exhaustive identification of all options 
for treatment -- if only one treatment is available (as is considered in Figure 1) six alternative decision 
options can be defined for comparison. These are listed in Table 1 with numbers 1 to 6.  
 
Fully structuring the problem using a decision tree also allows the identification of parameter inputs, 
estimates of which are needed for evaluation. Probability parameters inform stochastic nodes, and 
each is formulated as conditional on reaching the previous node on the pathway.  For example, the 
probability of having a positive test is conditioned on disease status being positive, and alternatively, 
negative.  Also, all possible pathways defined by the tree will need to be associated with expected 
health and cost outcomes (outcomes component). By knowing true disease status, the outcomes of 
treatment can be comfortably assumed independent of test results and only conditioned on true 
disease status. For the example in Figure 1, evidence on the outcomes of the following patients would 
be needed: D+ and treated, D+ and not treated, D- and treated and D- and not treated. These 
highlight the population-level trade-offs imposed by the imperfect tests: the gains of treating diseased 
patients compared to not treating them are expected to be valued at 0.8 QALY (1.8 QALY on average 
for diseased patients treated minus 1.0 QALY for diseased patients left untreated), as opposed to the 
0.6 QALYs expected to be lost by treating healthy patients in comparison to not treating them 
(2 QALY for healthy patients untreated minus 1.4 QALYs for those inappropriately treated). Any direct 
(adverse events) and indirect (opportunity costs) effects of the tests should also be considered.  
 
Evaluating total (net)health for each possible decision option consists of rolling-back the decision tree 
using the estimated parameter inputs described above; a detailed explanation of the calculations 
required and the results for the hypothetical example are shown in Table 1.  
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Table 1: Total (net) health associated with alternative strategies: dichotomous test results and single treatment 
strategies Test treat if t+ treat if t- tNH, QALY 
Incremental 
tNH 
strategies not involving testing  
  1 No test Yes Yes 1.64 
 2 No test No No 1.40 
 strategies with  test A alone 
  3 Test A Yes Yes 1.63 
 4 Test A Yes No 1.666 
 5 Test A No No 1.39 
 6 Test A No Yes 1.354 
 value of test A (4 vs. 1)  0.026 
Strategies  with Reference Standard (RS) 
  7 RS Yes No 1.68 
 8 Test A followed by RS (on - to A) Yes No 1.734 
 9 Test A followed by RS (on + to A) No No 1.602 
 value of testing (8 vs. 1)  0.094 
P 
Test without misclassification, without costs or direct health 
effects) 1.88  
value of heterogeneity (P vs. 1) 
 
0.24 
Notes on calculations: The (net)health of option 1 (not testing but treating all) can be calculated by considering the outcomes of 
diseased and healthy patients after treatment (i.e. 1.8*0.6+1.4*0.4), totalling 1.64 QALY. For options that involve testing, 
evaluating the decision tree implies determining the proportion of patients correctly and incorrectly classified according to 
disease status, and attributing the appropriate health outcomes. For option 4 (treating only if test is positive), the outcomes of 
each of four groups of patients are summed: (i) diseased patients that have been treated, P[D+] x P[T+|D+] x NHD+,treat, (ii) 
diseased patients that have not been treated, P[D+] x (1-P[T+|D+]) x NHD+,no treat, (iii) healthy patients that have been treated, (1-
P[D+]) x (1-P[T-|D-]) x NHD-,treat and, finally, (iv) those healthy patients that have not been treated, (1-P[D+]) x P[T-|D-] x NHD-,no 
treat. Additionally, the (net)health associated with the test itself is important, NHtest (here is assumed to be associated with -0.01 
QALY). For option 4, the total (net)health totals 1.666 QALY. 
 
Out of the 6 options (1 to 6), option 4 is the one that confers maximum population value and, as such, 
would be expected to be funded by the health care system. The value of the diagnostic test can be 
determined by comparing option 4 (i.e. the testing strategy associated with the highest value) with 
option 1 (i.e. the option that does not involve testing with the highest value) ± and for this example the 
value of the diagnostic test is 0.026 QALY per patient.  
 
It may also be of interest in an evaluation to describe the value of heterogeneity. This entails 
establishing the value of perfectly distinguishing subgroups and treating them appropriately. This can 
be simply done by assuming perfect sensitivity and specificity (both with probability of 1), and no costs 
or adverse events of testing (i.e. NHtest = 0) -- strategy P in Table 1. The value of heterogeneity (value 
of the perfect test) compares the value of P to the value of the best non-testing strategy (strategy 1 in 
our example). For the example in Figure 1, the value of heterogeneity is 0.24 QALY. The value of the 
perfect test provides a necessary condition for establishing the value of any new test (i.e. if the test 
costs more than this it can never be of value). The value of heterogeneity is much larger than the 
0.026 QALY conferred by the imperfect test A, indicating how much is lost from current suboptimal 
strategies  
 
Table 1 includes, for completeness, strategies 3 and 5, where all patients are tested but regardless of 
its results all are treated, or not treated, respectively.  Such strategies are, in this example, always 
 10/22 
 
DVVRFLDWHGZLWKZRUVHQHWKHDOWKRXWFRPHVWKDQVWUDWHJLHVDQGUHVSHFWLYHO\GXHWRWKHWHVW¶V
costs or adverse events. These strategies could have been reasonably excluded from consideration a 
priori.  
 
Drivers of value 
Given the mechanism of accrual of value specific to tests, there are three main aspects driving value. 
The first is the prevalence of disease. The higher is the prevalence the more likely LWLVWKDWµtreating 
DOO¶LVSUHIHUUHGWRWHVWLQJ± ultimately, as prevalence approximates 1, the costs that testing imposes 
may not compensate the ability to distinguish the few existing healthy patients. Conversely, the lower 
the probability of disease the more likely it is that µtreating none¶ is preferred to testing. Figure 2a 
illustrates the implications of varying the prevalence in the example above, ceteris paribus, in terms of 
(net)health for strategies 1, 2 and 4. The (net)health of the strategy that offers best value for each 
prevalence figure is highlighted in black, and shows that it is worth testing for a range of prevalence 
values between 8% and 63% (shaded grey area).  Figure 2b shows an alternative way of presenting 
these results, analogous to the graphical displays Phelps and Mushlin proposed(15): instead of the 
absolute (net)health, it presents the incremental (net)health in relation to the next best non-testing 
strategy.  
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Figure 2: Critical aspects of value: disease prevalence (ceteris paribus in relation to Figure 1). 
 
(a) total (net) health    
 
  
 
 
 
 
Another important driver of value is the performance of the test, i.e. its accuracy. Again using the 
example in Figure 1, sensitivity and specificity can be varied, ceteris paribus, to show their impact on 
results. The boundary of acceptance in Figure 3 can be used to identify the combinations of sensitivity 
and specificity that make testing worthwhile where prevalence is held fixed. The boundary represents 
combinations of sensitivity (x-axis)/specificity (y-axis) for which we should be indifferent between 
testing and treating all based on (net)health. Therefore, combinations to the right side of the line lead 
to recommendations to test, combinations to the left lead to recommendations of treating all.1 The 
grey line identifies the sensitivity and specificity values assumed in Figure 1. 
                                                          
1
 Note that testing is compared to treat all because, at the assumed prevalence, this is the best non-testing option. 
'RQ¶WWUHDW 
Test and treat 
Treat all  
: Range of values of probability of disease which support the use of a testing strategy 
(b) incremental total (net) health of testing in relation to next non-testing strategies  -- value of testing 
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Figure 3: Critical aspects of value: test performance (ceteris paribus in relation to Figure 1). 
   
 
 
The other main key driver of value is the value of the available treatments themselves. That is, the 
magnitude of health outcomes with each decision option (including the no-treatment option where 
relevant). For the example in Figure 1, a strategy of testing (strategy 4) is only of value insofar as the 
losses in health imposed by not treating some of the diseased (imperfect sensitivity) and treating 
some of the healthy (imperfect specificity) and additional losses due to costs of direct health effects of 
testing are greater than the losses imposed by treating all of the healthy patients who would be 
treated under strategy 1. This means any changes to the outcomes of treatment may affect the value 
of testing.  
 
Sequences of tests 
Continuing with the dichotomous test example, but now considering the reference standard test as an 
alternative test (here denominated test R), its use in isolation or in sequence with the imperfect test 
(here denominated test A) also become relevant. The reference test is, in this example, associated 
with significant direct health losses (NHR = 0.2 QALY) but, by definition, has perfect sensitivity and 
specificity. In this context, options 7, 8 and 9 were deemed as relevant options for comparison (see 
Table 1). Strategy 7 uses the reference test alone, and strategies 8 and 9 use it only in patients who 
tested negative and positive to test A, respectively.  Note that other options were omitted, for example 
those involving treating patients classified as negative2.  The strategy conferring the most (net)health 
is strategy 8, and the value of testing when the options are extended in this way is higher at 0.094. In 
relation to the use of test A in isolation, the sequence represents an almost fourfold improvement in 
(net) health gains. However, it still falls short of the value of heterogeneity, evaluated at 0.24 QALYs 
                                                          
2 This option can safely be ignored only if outcomes of treating are undoubtedly better in the diseased, and equal or worse in 
the non-diseased 
Treat all  
     : Area for which 
combinations of vales of 
sensitivity and specificity 
provide higher (net) health 
than treating all 
 
-- : Combination of values 
assumed in Fig 1 
Test and treat 
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in this example, indicating that further developments of the tests involved (e.g. aimed at reducing 
adverse events of the RS or reducing misclassification with test A) could be of value.  
 
How do prognostics differ from diagnostics? 
The above principles on the accrual of value hold true for both diagnostics and prognostics(25). 
However, prognostics differ from diagnostics in that they aim to predict uncertain events occurring in 
the future that cannot be known at the stage of testing.(33) The outcomes component cannot be 
assumed independent of test results. An important consequence is that evidence becomes specific to 
the context of the primary research informing outcomes, limiting generalisability.(34) The same is true 
for diagnostic tests without a perfect reference standard. The bottom panel in Figure 1 illustrates how 
the decision tree diagram would change for a prognostic measure (and a diagnostic test without a 
perfect reference standard), and lists the inputs required.  
 
Beyond dichotomous 
Clinical investigations are increasingly complex, with many moving beyond simply detecting the 
presence or absence of a disease. One aspect of this complexity is the format of test results, which 
may range from descriptive information (e.g. signs and symptoms), to continuous results (e.g. 
physiological quantities such as cholesterol or blood pressure), to complex imaging technologies or 
composite measures using a series tests (e.g. TNM Classification of Malignant Tumours). Given that 
clinical policy can only consider as many treatment groups as the number of treatment strategies 
available (including no treatment), more complex test results will require more nuanced classification 
rules. In this section, we will examine how value can be established when tests go beyond reporting 
dichotomous results. For illustrative purposes we will focus on tests reporting continuous results.  
 
Diagnostics for which there is a reference standard 
The first example considered is a test used to restrict the use of a single treatment. The test aims to 
identify two subgroups (healthy and diseased) but does so imperfectly as the distributions of test 
results in the two subgroups may overlap²for certain values of the test one cannot be sure whether 
the patient is diseased or healthy. A hypothetical example is shown in plot (a) in Figure 4.  In this 
case, a single cut-off value may be used as classification rule but, in changing the cut-off, sensitivity 
and specificity will vary. The Receiver Operating Characteristic (ROC) curve(32) depicts the 
relationship between these two quantities as the cut-off changes²plot (b) in Figure 4, with sensitivity 
on the y-axis and 1-specificity on the x-axis. The ROC curve, however, cannot inform which point of 
the curve generates the highest level of (net)health for the population tested. It is more useful to 
present directly the (net)health attained by using alternative cut-off points as illustrated in plot (c) in 
Figure 4. Superimposed in this plot is the boundary of acceptance of the test, which shows that there 
is only value to testing if the cut-off is between 69 and 94 and that the maximum (net)health is 
attained at a cut-off of 85.   
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Figure 4 : Diagnostics: continuous results and two treatments available 
(a) Distribution of test results in the two populations, healthy and diseased   
 
(b) ROC curve 
 
(c) total (net) health associated with relevant test/treat strategies -- acceptance boundary 
 
 
 
Healthy Diseased 
: Range of cut-off values that 
support the use of a testing 
strategy 
 
Vertical grey line indicates the 
cut-off associated with maximum 
expected (net) health  
1.00 
0.01 
1.00 
0.07 
0.96 
0.31 
0.76 
0.69 
0.38 
0.93 
0.10 
0.99 
sens 
spec  
Treat all 
Test and treat 
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The second example extends the previous one to consider three subgroups, three treatment options 
(e.g. two available treatments and no treatment), and two cut-off values for the test results. Plot(a) in 
Figure 5 shows an example of the distribution of test results within each the three subgroups. 
Misclassification exists as the distributions of test results in each subgroup overlap but, given there 
are three subgroups, sensitivity and specificity cannot be used as these are only used for 
dichotomous tests. Instead, analogous measures can be used: probability of a patient in a given 
JURXSM ^«`EHLQJLGHQWLILHGE\WKHWHVWDVEHORQJLQJWRJURXSN ^«`)RUH[DPSOHIRUWKRVHLQ
group 1 (D=1), two quantities are needed to describe the accuracy of the test:  P[T=1|D=1] (correctly 
identified) and P[T=2|D=1], with the remainder summing to 1 (i.e. P[T=3|D=1] = 1- P[T=2|D=1] - 
P[T=2|D=1]). Additionally, evidence is needed on the outcomes of all three treatment options when 
used in each of the three patient groups. With such evidence, one can identify combinations of the 
cut-offs that return the most health for the population. To display this information, plot (b) in Figure 5 
uses contour lines, where each line represents combinations of cut-offs that lead to equal (net)health 
gains when compared to the next best alternative (which in this example is to treat none). These 
contour lines are only shown for the acceptance region for testing (shaded in the figure), i.e. where 
incremental (net)health as a result of testing is equal to, or above, 0. The plot shows that a lower cut-
off of 73 and an upper cut-off of 90 lead to highest gains. 
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Figure 5: Diagnostics: continuous results and three treatments available  
 
(a) Distribution of test results in the three populations   
 
b) incremental total (net) health of testing in relation to next non-testing strategies  -- contour plot with shaded acceptance 
region. Contour lines represent the combinations of cut-offs that lead to equal net health gain compared to the next best 
alternative. So, the 0.01 line represents the combinations associated with a net health gain of 0.01 QALYs. 
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Prognostics and diagnostics without reference test 
In this subsection we illustrate how a hypothetical prognostic measure with continuous results (risk 
score, for example) can be evaluated within HTA. A possible distribution of test results in the 
population of interest is shown in plot(a) in Figure 6. Panel (b) of Figure 6 shows the (net)health of 
treating versus not treating patients with a given test result²this is no more than a marker-by-
treatment predictiveness curve(34) or a treatment effect pattern plot(35), using (net)health as the 
outcome of interest. This plot can be used directly (i.e. independently of panel a) to define threshold 
scores above which treatment should be recommended²in this example the threshold should be set 
at 139 where the (net)health of treating becomes higher than that of not treating.  
 
Figure 6: Prognostics: two treatments, 1 cut-off value. 
(a) Distribution of the prognostic score in the population 
 
(b) (net) health conditional on test results 
 
(c) population (net) health for a range of cut-off scores 
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However, a cut-off lower than 139 can still prove beneficial in relation to not treating. This is because 
the gains from treating those that benefit the most (at very high risk scores) still compensate for the 
losses imposed on those treated at a lower score than the optimal. Plot (c) in Figure 6 shows the 
average (net)health of the population when treating only those above a cut-off, and varies the cut-off 
values considered. The use of the prognostic test for clinical decision making is worthwhile for cut-off 
values above 134, despite the maximum (net)health still being generated at the cut-off of 139. Note 
that the distribution of test results in the population of interest (panel a) matters for this cut-off.  
 
 
DISCUSSION     
 
This paper lays out a coherent framework for the assessment of diagnostic and prognostic tests for 
HTA using a linked-evidence(5), or decision modelling, approach. It is solidly grounded on the indirect 
mechanism of value accrual for these health technologies that can be summarised using three 
interlinked components: classification (using test results to define treatment groups), choice (in terms 
of treatment) and outcomes. Importantly, this paper proposes a series of innovative graphical displays 
aiming to better inform decision making. 
 
Implications for appraisal processes 
The indirect and complex mechanisms of value for diagnostic and prognostic tests means that 
GHFLVLRQVRYHUWKHµXSVWUHDP¶WHVWVWKDWDUHXVHGWRUHVWULFWWUHDWPHQWWRSDUWLFXODUJURXSVFDQQRWEH
VHSDUDWHGIURPGHFLVLRQVRYHUµGRZQVWUHDP¶WUHDWPHQWV,WLV however, seldom the case that these 
decisions are considered simultaneously. Diagnostic decisions reached by NICE, for example, cannot 
issue recommendations on treatments. Also, the typical evaluation question µZKLFKSDWLHQWVWRWUHDW¶ 
should be broadened to a question of µZKHQWRWUHDW¶ which is closer to clinical practice where 
treatment decisions are reviewed longitudinally over time.(31) 
 
To inform decision making, all possible combinations of whether and when to test, test(s) to use, 
classification rules and treatment choices should be evaluated and compared. This may mean the 
evaluation becomes very complex, with many options to compare, but such complexity is necessary 
to identify the combination generating the most health for the population. It may prove to be 
analytically challenging, and therefore removing some of the options from the analyses may be 
desirable. A first consideration may be relevance, which can be established a priori based on specific 
characteristics of the tests or its purpose/role.(11) For example, if treatment cannot be undertaken 
without a test, e.g. tumor location in breast cancer surgery, a strategy of not testing and treating 
cannot be considered. However, there may still remain a multitude of options left for evaluation. With 
a value-based approach, options that do not retain significant possibility of being effective or cost-
effective (given the existing uncertainties) can also be confidently excluded from the results. For 
example, Colbourn et al(36) in evaluating prenatal testing for group B streptococcal infection, 
alongside antibiotic treatment and vaccination, retained for analysis only combinations of interventions 
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that had more than a 1% probability of being cost effective, and discarded those remaining. Complex 
evaluations involving multiple strategies could also explore the use of operations research 
methods(37), such as optimisation where the number of combinations is large, or Markov decision 
processes for sequential testing [example in (38)].  
 
A final critical implication for policy of the interlinked nature of the components of value is that a 
change in any element generates the need for re-appraisal. For example, if a new treatment emerges, 
or the price of one of the treatments changes, the value of upstream tests should be re-assessed, 
with classification rules and optimal treatment choices reviewed. Within a linked evidence approach 
re-appraisal is, in principle, simple as the evidence on components that are unchanged can still be 
used. 
 
End-to-end studies 
Clinical research on diagnostic tests has recently moved from exclusively focussing on accuracy 
evidence to recently highlighting the need for end-to-end, or outcome, studies(39)± clinical trials 
randomising patients to testing strategies (which may be a testing strategy and one not involving 
testing) to detect differences in health outcomes. Some policy makers in HTA have explicitly stated a 
preference for such end-to-end studies(3). These studies, however, embed pre-specified choices on 
classification and treatment, not allowing for the mechanisms of value to be made explicit and 
compromise on generalisability and adaptability to other settings. Importantly, where a new treatment 
emerges and re-appraisal is necessary, evidence from an original end-to-end study may become 
irrelevant. Additionally, given the aim of detecting overall outcome differences, the sample sizes for 
such studies may need to be unfeasibly high (especially for less prevalent diseases) with the 
associated costs potentially not worth the limited evidence they produce. Perhaps because of their 
costs, the availability of end-to-end trials is as yet very limited.(40) 
 
Uncertainty 
In the context of HTA, uncertainty refers specifically to uncertainty in knowledge that can be resolved 
through further research; uncertainty arises from sampled data, the need for extrapolation or the use 
of judgements. However, in the diagnostics literature, the term uncertainty has, confusingly, also been 
used to reflect imperfect performance of tests in identifying diseased patients. Accuracy cannot be 
LPSURYHGZLWKIXUWKHUUHVHDUFKEXWRQO\E\GHYHORSLQJDµEHWWHU¶OHVVLPSHUIHFWWHVWRUE\XVLQJD
sequence of complementary tests).   
 
It is important that uncertainty in the evidence base is explicitly considered, so that decision makers 
can be confident in making recommendations where a lower level of decision uncertainty presents. 
But, perhaps more importantly, a careful analysis of uncertainty will help determine whether further 
research is worthwhile and whether to condition the use of a particular technology only in the context 
of research.(39, 40) Given that regulatory processes for these technologies do not have as strict 
requirements for clinical evidence to be presented, it is especially important that any implications of 
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uncertainty are scrutinised. Uncertainty can be reflected through using both deterministic and 
probabilistic sensitivity analysis,(43) Careful consideration should be given to the analyses conducted 
with, for example, the use of bivariate distributions for considering uncertainty in test accuracy given 
the clear correlation between sensitivity and specificity.(44) 
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